MetLife Investment Management’s Terns Pharmaceuticals TERN Stock Holding History

MetLife Investment Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.75M	Buy	52,215 +4,277	+9%	+$176K	0.01%	895
2025 Q4	$1.94M	Buy	47,938 +2,342	+5%	+$54.1K	0.01%	1089
2025 Q3	$342K	Hold	45,596	–	–	﹤0.01%	2005
2025 Q2	$170K	Buy	45,596 +23,716	+108%	+$74.1K	﹤0.01%	2274
2025 Q1	$60.4K	Sell	21,880 -21,880	-50%	-$89.4K	﹤0.01%	2669
2024 Q4	$242K	Buy	43,760 +9,500	+28%	+$64.3K	﹤0.01%	2202
2024 Q3	$286K	Hold	34,260	–	–	﹤0.01%	2091
2024 Q2	$233K	Buy	34,260 +11,148	+48%	+$67.5K	﹤0.01%	2150
2024 Q1	$152K	Hold	23,112	–	–	﹤0.01%	2340
2023 Q4	$150K	Hold	23,112	–	–	﹤0.01%	2396
2023 Q3	$116K	Hold	23,112	–	–	﹤0.01%	2502
2023 Q2	$202K	Buy	+23,112	New	+$269K	﹤0.01%	2271

Other funds holding TERN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

MetLife Investment Management's TERN Position: Q1 2026 in Review

MetLife Investment Management increased its Terns Pharmaceuticals (TERN) stake by 8.9% in Q1 2026, buying an estimated $176K and bringing the position to 52,215 shares worth $2.75M. The position accounts for 0.01% of the portfolio, ranked #895.

MetLife Investment Management first reported a position in TERN in Q2 2023 and has held it in 12 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

MetLife Investment Management held 52,215 shares of Terns Pharmaceuticals worth $2.75M as of Q1 2026.
MetLife Investment Management bought 4,277 Terns Pharmaceuticals shares in Q1 2026, an estimated $176K.
Terns Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q1 2026, its #895 holding.
MetLife Investment Management first reported a position in Terns Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.